NCT06893861 Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
| NCT ID | NCT06893861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Naples |
| Condition | Endometrial Carcinoma (EC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,100 participants |
| Start Date | 2023-07-06 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,100 participants in total. It began in 2023-07-06 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.
Eligibility Criteria
Inclusion Criteria: 1. Female sex 2. Age between 50 and 80 years 3. Willingness to participate in the study and signing of the informed consent 4. Clinical condition of post-menopause Exclusion Criteria: 1. Previous hysterectomy 2. Hormone replacement therapy 3. Immunosuppressive therapy
Contact & Investigator
Antonella De Luca
PRINCIPAL INVESTIGATOR
IRCCS I.N.T. "G. Pascale"
Frequently Asked Questions
Who can join the NCT06893861 clinical trial?
This trial is open to female participants only, aged 50 Years or older, up to 80 Years, studying Endometrial Carcinoma (EC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06893861 currently recruiting?
Yes, NCT06893861 is actively recruiting participants. Contact the research team at a.deluca@istitutotumori.na.it for enrollment information.
Where is the NCT06893861 trial being conducted?
This trial is being conducted at Naples, Italy.
Who is sponsoring the NCT06893861 clinical trial?
NCT06893861 is sponsored by National Cancer Institute, Naples. The principal investigator is Antonella De Luca at IRCCS I.N.T. "G. Pascale". The trial plans to enroll 3,100 participants.